Ryan P Jajosky, Kashyap R Patel, Jerry William L Allen, Patricia E Zerra, Satheesh Chonat, Diyoly Ayona, Cheryl L Maier, Dominique Morais, Shang-Chuen Wu, C John Luckey, Stephanie C Eisenbarth, John D Roback, Ross M Fasano, Cassandra D Josephson, John P Manis, Li Chai, Jeanne E Hendrickson, Krystalyn E Hudson, Connie M Arthur, Sean R Stowell
Antibodies against fetal red blood cell (RBC) antigens can cause hemolytic disease of the fetus and newborn (HDFN). Reductions in HDFN due to anti-RhD antibodies have been achieved through use of Rh immune globulin (RhIg), a polyclonal antibody preparation that causes antibody-mediated immunosuppression (AMIS), thereby preventing maternal immune responses against fetal RBCs. Despite the success of RhIg, it is only effective against 1 alloantigen. The lack of similar interventions that mitigate immune responses toward other RBC alloantigens reflects an incomplete understanding of AMIS mechanisms...
September 21, 2023: Blood